Tubarao

Major depressive disorder MDD is a common and disabling mental health condition, with many patients not fully improving after usual antidepressant treatments. This trial, known as the ANANDA trial, is designed to study the effects of full-spectrum cannabidiol CBD oil as an additional treatment for adults with treatment-resistant MDD. Researchers aim to evaluate the safety, tolerability, and benefits of CBD oil alongside stable antidepressant medication. Participants will be randomly assigned to one of two groups one receiving full-spectrum CBD oil and the other receiving a placebo oil. Both treatments are given under the tongue sublingually for 12 weeks, following a dose adjustment schedule based on individual response and safety. The CBD oil contains cannabidiol and other natural components from Cannabis sativa, while the placebo uses medium-chain triglyceride MCT oil and looks identical to maintain blinding. Throughout the study, participants will attend assessments at the start, Week 4, and Week 12 to measure depressive symptoms, anxiety, sleep quality, stress levels, and any side effects. Blood samples will be taken at the beginning and end of the study to analyze biological markers related to inflammation and neuroendocrine function. The main focus is on changes in depression severity after 12 weeks, with additional attention to anxiety, sleep, quality of life, and safety. The study lasts about three months, during which participants continue their regular antidepressant treatment.

Researchers are evaluating the potential effects of full-spectrum cannabigerol CBG oil on cognitive and behavioral symptoms in adolescents aged 12 to 17 years diagnosed with Attention-DeficitHyperactivity Disorder ADHD. This randomized, double-blind, placebo-controlled clinical trial aims to study adolescents with ADHD who have not responded adequately to previous treatments. ADHD is a neurodevelopmental disorder characterized by inattention, hyperactivity, and impulsivity that impacts academic, social, and emotional functioning. Participants will be randomly assigned to receive either full-spectrum CBG oil or a placebo oil for 12 weeks. The CBG oil contains cannabigerol, cannabidiol, and a low dose of tetrahydrocannabinol and is given sublingually following a structured dose titration schedule starting with low doses and adjusted based on clinical response and tolerability. The placebo group will receive a matched medium-chain triglyceride MCT oil. Clinical assessments will occur at baseline, week 6, and week 12, with weekly remote monitoring to track adherence, safety, and dose adjustments. Throughout the study, participants will undergo clinical evaluations including ADHD symptom severity measured by the SNAP-IV questionnaire, quality of life assessments, emotional symptom scales, and sleep pattern questionnaires. Weekly remote monitoring will assess treatment adherence, tolerability, adverse events, and overall clinical progress. The study aims to provide rigorous data on the efficacy, tolerability, and safety of CBG oil in adolescents with ADHD, with total participation lasting 12 weeks.